Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Potassium Citrate). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Urokit wax matrix extend-release tablet is indicated for renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Severe hypocitraturia (urinary citrate below 150 mg/day): treatment is usually started at 60 mEq per day, taken as 30 mEq twice daily or 20 mEq three times daily with meals, within 30 minutes after meals, or with a bedtime snack. Mild to moderate hypocitraturia (urinary citrate above 150 mg/day): treatment is usually started at 30 mEq per day, taken as 15 mEq twice daily or 10 mEq three times daily with meals, within 30 minutes after meals, or with a bedtime snack. Pediatric use: safety and effectiveness in children have not been established.
Side Effects
Some patients may develop mild digestive issues such as stomach discomfort, vomiting, diarrhea, loose stools, or nausea. Taking the dose with meals or snacks, or lowering the dosage, may help ease these effects.
Cautions & Contraindications
Warnings & Precautions
Hyperkalemia: in patients whose bodies cannot excrete potassium normally, Urokit can bring on hyperkalemia and cardiac arrest. This potentially fatal rise in potassium can develop quickly and without any warning symptoms. Urokit extended release tablets should not be given to patients with chronic renal failure or any other condition that impairs potassium excretion, such as severe myocardial damage or heart failure. Gastrointestinal lesions: if severe vomiting, abdominal pain or gastrointestinal bleeding occurs, Urokit extended release tablets should be stopped right away and the patient checked for possible bowel perforation or obstruction.
Contraindications
Patients with hyperkalemia, or with conditions that make hyperkalemia more likely. Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown. Patients in whom passage of the tablet through the gastrointestinal tract may be arrested or delayed, such as those with delayed gastric emptying, esophageal compression, or intestinal obstruction or stricture. Patients with peptic ulcer disease. Patients with an active urinary tract infection. Patients with renal insufficiency, defined as a glomerular filtration rate of less than 0.7 mL/kg/min.